Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

When Eval­u­ate Phar­ma crunched the like­ly drug sales num­bers for the big 10, 2 stood out. 

Take­da, with its big Shire buy­out un­der its belt, is set to al­most dou­ble its world­wide sales record for 2018 over 5 years, putting it in the big 10 — the 9th spot, to be ex­act — which is ex­act­ly where CEO Christophe We­ber wants to be. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.